Questcor Pharmaceuticals Inc (QCOR)

pos +0.00
Today's Range: 94.19 - 97.80 | QCOR Avg Daily Volume: 1,620,800
Last Update: 07/25/14 - 3:59 PM EDT
Volume: 0
YTD Performance: 74.29%
Open: $0.00
Previous Close: $96.93
52 Week Range: $46.00 - $97.80
Oustanding Shares: 60,977,015
Market Cap: 5,953,531,036
6-Month Chart
TheStreet Ratings Grade for QCOR
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 2 2 2 3
Moderate Buy 0 0 0 0
Hold 4 4 4 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.33 2.33 2.33 1.80
Latest Dividend: 0.30
Latest Dividend Yield: 1.24%
Dividend Ex-Date: 06/27/14
Price Earnings Ratio: 16.95
Price Earnings Comparisons:
QCOR Sector Avg. S&P 500
16.95 18.30 28.93
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
16.44% 97.13% 252.66%
Revenue 56.90 5.94 0.90
Net Income 48.00 7.34 1.01
EPS 51.90 7.91 1.06
Earnings for QCOR:
Revenue 0.80B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $2.06 $2.22 $7.49 $7.91
Number of Analysts 1 1 1 1
High Estimate $2.06 $2.22 $7.49 $7.91
Low Estimate $2.06 $2.22 $7.49 $7.91
Prior Year $1.60 $1.53 $5.01 $7.49
Growth Rate (Year over Year) 28.75% 45.10% 49.50% 5.61%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
A wave of M&A in the health sector makes sense.
But in the real world they're wrong, as the Questcor buyout demonstrates.

Off the Charts Real Money Pro($)

America Movil is showing significant relative weakness this year.
Oct 30, 2013 | 7:58 AM EDT
QCOR raised its numbers, according to Jefferies. Very robust Acthar growth  in rheumatology. $76 price target and Buy rating.
Aug 21, 2013 | 7:25 AM EDT
QCOR was upgraded from Neutral to Buy, Bank of America/Merrill Lynch said. $80 price target. Acthar sales are driving growth. 
Jul 31, 2013 | 8:36 AM EDT
QCOR was upgraded from Neutral to Overweight, Piper Jaffray said. $74 price target. Acthar can drive near-term growth. 
Jun 21, 2013 | 7:47 AM EDT
QCOR was downgraded from Buy to Neutral, Bank of America/Merrill Lynch said. $51 price target. Acthar could face increased competition....
Jun 21, 2013 | 7:25 AM EDT
QCOR was upgraded from Perform to Outperform, Oppenheimer said. $57 price target. New analyst believes that Acthar can drive near-term ...
Feb 27, 2013 | 8:04 AM EST
Shares of QCOR now seen reaching $38, Jefferies said. Estimates also raised on Strong 4Q with robust 2013 outlook. Buy rating.
Martin Zweig had a colorful style and an insightful approach.

Columnist Conversations

Index Chart of the Day: SPX and RUT Divergence SPX vs. RUT (YTD) View Chart »&nbs...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
The S&P 500 index finished the week unchanged, but the VIX was up 5%, the divergence sending a bit of a mi...
Weyerhaeuser has been struggling since testing the 2013 highs last month. The stock extended a powerful...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.